Tetanus toxoid, Diphtheria toxoid, and Bordetella pertussis antigens (DTaP (for pediatric formulation), Tdap (for adolescent/adult formulation))

Tetanus toxoid, diphtheria toxoid, and Bordetella pertussis antigens are inactivated bacterial toxins and purified protein subunits used as immunogens in vaccines to prevent tetanus (caused by *Clostridium tetani*), diphtheria (*Corynebacterium diphtheriae*), and pertussis (*Bordetella pertussis*) infections. Tetanus and diphtheria toxoids are chemically inactivated toxins (usually by formaldehyde treatment) that retain immunogenicity but lack toxicity. Bordetella pertussis antigens used in acellular vaccines include pertussis toxin (PT, detoxified), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae (FIM) types 2 and 3. These antigens are not endogenous human molecules, nor do they represent “targets” for drug therapy, but are instead foreign antigens that evoke specific protective immune responses when administered as vaccines. Combination vaccines containing these antigens are available under various names and formulations (DTaP, Tdap), recommended for children, adolescents, adults, and pregnant women in specific dosing schedules to confer immunity against these important bacterial infections. This entity does not represent a typical molecular target suitable for drug targeting or biomarker identification outside the context of immunization efficacy/monitoring.

Other names

Diphtheria-Tetanus-Pertussis vaccine antigensDTP antigensDTaP antigensTdap antigensDPTDTPDTPa (acellular variant)

Induction of adaptive immunity (Vaccines containing these antigens prompt immune memory, stimulating production of neutralizing antibodies and T cell responses, which confer protection against the toxins/pathogens upon exposure)